<DOC>
	<DOCNO>NCT00452634</DOCNO>
	<brief_summary>3-Hydroxy-3-methylglutaryl CoA reductase inhibitor , commonly refer statin , proven therapeutic preventative effect cardiovascular disease . Recently , emerge interest use anticancer agent base preclinical evidence antiproliferative , proapoptotic , anti-invasive , radiosensitizing property . Inhibition 3-hydroxy-3-methylglutaryl CoA reductase statins interfere rate-limiting step mevalonate pathway , lead reduce level mevalonate downstream product , many play important role critical cellular function membrane integrity , cell signaling , protein synthesis , cell cycle progression . Perturbations process neoplastic cell statin may therefore result control tumor initiation , growth , metastasis . The statin demonstrate growth inhibitory activity cancer cell line preclinical tumor model animal . Simvastatin , member statin family , profoundly impaired basal growth factor-stimulated SCLC cell growth vitro induce apoptosis . SCLC cell treat simvastatin sensitized effect chemotherapeutic agent etoposide . Moreover , SCLC tumour growth vivo inhibit simvastatin . Therefore , investigator conduct phase II trial evaluate efficacy &amp; toxicity irinotecan/cisplatin plus simvastatin patient chemo-naïve ED-SCLC .</brief_summary>
	<brief_title>Irinotecan/Cisplatin Plus Simvastatin Extensive Disease-Small Cell Lung Cancer ( ED-SCLC )</brief_title>
	<detailed_description>Cisplatin-30 mg/m2 day 1 8 repeat q 3 week Irinotecan-65 mg/m2 day1 8 repeat q 3 week Simvastatin 40 mg per day orally D1 cycle 1 Treatment continue disease progression , unacceptable toxicity , patient ' refusal .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Histologic cytologic diagnosis SCLC Extensivestage disease , define disease extend beyond one hemithorax involve contralateral mediastinal , hilar supraclavicular lymph node , and/or pleural effusion . No prior chemotherapy , immunotherapy , radiotherapy Performance status 0 , 1 , 2 ECOG criterion . At least one unidimensional measurable lesion meeting Response Evaluation Criteria Solid Tumors ( RECIST . 2000 ) . Patient compliance allow adequate followup . Adequate hematologic ( WBC count ≥ 4,000/mm3 , platelet count ≥ 150,000/mm3 ) , hepatic ( bilirubin level ≤ 1.5 mg/dL , AST/ALT ≤ 80 IU/L ) , renal ( creatinine concentration ≤ 1.5 mg/dL ) function . Informed consent patient patient 's relative . Males female least 18 year age . If female : childbearing potential either terminate surgery , radiation , menopause , attenuate use approve contraceptive method ( intrauterine device [ IUD ] , birth control pill , barrier device ) 3 month trial . If male , use approve contraceptive method study 3 month afterwards . Females childbearing potential must urine negative HCG test within 7 day prior study enrollment . No concomitant prescription include cyclosporin A , valproic acid , phenobarbital , phenytoin , ketoconazole . Patients brain metastasis allow unless clinically significant neurological symptom sign Inability comply protocol study procedure . A serious concomitant systemic disorder , opinion investigator , would compromise patient 's ability complete study . A serious cardiac condition , myocardial infarction within 6 month , angina , heart disease , define New York Heart Association Class III IV . Second primary malignancy clinically detectable time consideration study enrollment . Concurrent administration antitumor therapy . Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Irinotecan</keyword>
	<keyword>cisplatin</keyword>
	<keyword>Simvastatin</keyword>
	<keyword>Extensive disease</keyword>
	<keyword>SCLC</keyword>
</DOC>